NERLYNX (neratinib) Tablets Approved for HER2+ Breast Cancer in the Extended Adjuvant Setting
CARY, N.C. (July 21, 2017) — Biologics, Inc., a McKesson Specialty Health oncology pharmacy services company, announced today it has been selected to be in the limited distribution network for Puma Biotechnology, Inc.’s new product, NERLYNX, a kinase inhibitor approved by the U.S. Food and Drug Admi...
Source: McKesson News - Category: Information Technology Source Type: news
More News: Biotechnology | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Information Technology